The USC Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University and the Kenneth Norris Jr. Cancer Hospital, which is an integral part of the Cancer Center. The Center underwent a major expansion with the addition of the Norman Topping Tower in 1996 and the Harlyne Norris Research Tower in 2007. The Center's 198 members are organized into five thematic and five translational research programs, including a """"""""bridge"""""""" program in developmental therapeutics. The thematic programs are headed by senior investigators in the fields of molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research. The translational programs, which provide focus to our transdisciplinary research efforts, are in developmental therapeutics, genitourinary cancers, gastrointestinal cancers, women's cancers and leukemia and lymphoma. This application is for: 1) partial salary support for the Center's senior leadership, who are responsible for planning and overseeing our research efforts;2) support for program planning and evaluation to keep the Center at the forefront of cancer research;3) support for the administrative infrastructure of the Center;4) partial support for the Center's 11 shared resources which facilitate the conduct of our peer-reviewed research;and 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion and to fund innovative pilot projects. Continued funding from the Cancer Center Core Support Grant will allow us to build on our strengths in basic and population-based research and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country. Cancer Center members currently hold grants totaling $125 million in direct costs, with $43 million of that coming from NCI (all exclusive of the CCSG).
The USC Norris Comprehensive Cancer Center provides the infrastructure and resources to facilitate and foster translational research for the development of more effective prevention, diagnosis, treatment of cancer.
|Valentin-Torres, Alice; Savarin, Carine; Barnett, Joslyn et al. (2018) Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. J Neuroinflammation 15:121|
|Ricker, Charité N; Koff, Rachel B; Qu, Chenxu et al. (2018) Patient communication of cancer genetic test results in a diverse population. Transl Behav Med 8:85-94|
|Jayne, Jordanna G; Bensman, Timothy J; Schaal, Justin B et al. (2018) Rhesus ?-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol 58:310-319|
|Tobin, Jessica; Miller, Kimberly A; Baezconde-Garbanati, Lourdes et al. (2018) Acculturation, Mental Health, and Quality of Life among Hispanic Childhood Cancer Survivors: A Latent Class Analysis. Ethn Dis 28:55-60|
|Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182|
|Lee, Brian H; Stallcup, Michael R (2018) Different chromatin and DNA sequence characteristics define glucocorticoid receptor binding sites that are blocked or not blocked by coregulator Hic-5. PLoS One 13:e0196965|
|Matsusaka, S; Wu, A H; Cao, S et al. (2018) Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J 18:262-269|
|Woodham, Andrew W; Cheloha, Ross W; Ling, Jingjing et al. (2018) Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res 6:870-880|
|Veyseh, Maedah; Ricker, Charite; Espenschied, Carin et al. (2018) Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Front Oncol 8:259|
|Vannini, Ivan; Fanini, Francesca; Fabbri, Muller (2018) Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 48:128-133|
Showing the most recent 10 out of 842 publications